GlassScriptPhysician profile
Kevin Gershuny
NPI 1023341047
$2,591.87
in general payments reported to CMS, 2019-2025
33 companies · $675 in 2025
The $675 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $113 · 2021: $258 · 2022: $357 · 2023: $410 · 2024: $669 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $618.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $181.79 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.02 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $167.02 | 2021-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $166.99 | 2024-2025 | Farxiga, Airsupra, Lokelma |
| Pfizer INC. | $162.45 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $108.82 | 2019-2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $104.84 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $99.04 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $98.65 | 2020-2025 | Verquvo, Capvaxive, Steglatro |
| Lundbeck LLC | $94.35 | 2020-2025 | Rexulti |
| Exact Sciences Corporation | $82.26 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $75.73 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $58.36 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.65 | 2022-2023 | Jardiance, Synjardy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.87 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.79 | 2021-2022 | |
| Mylan Specialty L.P. | $30.25 | 2022-2023 | Yupelri |
| Boston Scientific Corporation | $29.75 | 2024 | Emblem Mri S-Icd |
| Collegium Pharmaceutical, INC. | $25.37 | 2022-2025 | Belbuca |
| Actelion Pharmaceuticals US, INC. | $20.54 | 2024 | Opsumit, Uptravi |
| Seqirus USA INC | $19.00 | 2025 | Flucelvax, Fluad |
| Harmony Biosciences LLC | $18.09 | 2025 | |
| Nestle Healthcare Nutrition INC. | $16.44 | 2021 | |
| Sanofi Pasteur INC. | $16.18 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.70 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $15.00 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.46 | 2024 | Zilretta, Iovera |
| Cequr Corporation | $14.44 | 2023 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $14.29 | 2024 | Gvoke Hypopen |
| Almatica Pharma LLC | $12.48 | 2022 | |
| Sun Pharmaceutical Industries INC. | $11.97 | 2021 | |
| Scilex Pharmaceuticals INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Gershuny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.